LEXARIA BIOSCIENCE CORP(NASDAQ:LEXX) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 4 out of 10 to LEXX. LEXX was compared to 198 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for LEXX as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, LEXX is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

LEXX had negative earnings in the past year.

LEXX had a negative operating cash flow in the past year.

LEXX had negative earnings in each of the past 5 years.

In the past 5 years LEXX always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -108.13%, LEXX is not doing good in the industry: 77.27% of the companies in the same industry are doing better.

The Return On Equity of LEXX (-131.33%) is worse than 62.63% of its industry peers.

		Industry Rank	Sector Rank
ROA	-108.13%
ROE	-131.33%
ROIC	N/A

ROA(3y)-124.81%

ROA(5y)-108.73%

ROE(3y)-127.55%

ROE(5y)-113.67%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

LEXX has a Gross Margin of 99.49%. This is amongst the best in the industry. LEXX outperforms 98.99% of its industry peers.

LEXX's Gross Margin has improved in the last couple of years.

The Profit Margin and Operating Margin are not available for LEXX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	99.49%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y9.01%

GM growth 5Y1.71%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

LEXX does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, LEXX has more shares outstanding

LEXX has more shares outstanding than it did 5 years ago.

There is no outstanding debt for LEXX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -0.27, we must say that LEXX is in the distress zone and has some risk of bankruptcy.

LEXX has a Altman-Z score (-0.27) which is in line with its industry peers.

There is no outstanding debt for LEXX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-0.27

ROIC/WACCN/A

WACC8.3%

2.3 Liquidity

LEXX has a Current Ratio of 4.24. This indicates that LEXX is financially healthy and has no problem in meeting its short term obligations.

LEXX has a better Current ratio (4.24) than 65.66% of its industry peers.

A Quick Ratio of 4.24 indicates that LEXX has no problem at all paying its short term obligations.

Looking at the Quick ratio, with a value of 4.24, LEXX is in the better half of the industry, outperforming 67.17% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	4.24
Quick Ratio	4.24

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

LEXX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 14.71%, which is quite good.

LEXX shows a strong growth in Revenue. In the last year, the Revenue has grown by 36.14%.

The Revenue has been growing by 16.11% on average over the past years. This is quite good.

EPS 1Y (TTM)14.71%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-150%

Revenue 1Y (TTM)36.14%

Revenue growth 3Y-13.6%

Revenue growth 5Y16.11%

Sales Q2Q%20%

3.2 Future

Based on estimates for the next years, LEXX will show a small growth in Earnings Per Share. The EPS will grow by 4.99% on average per year.

The Revenue is expected to grow by 181.98% on average over the next years. This is a very strong growth

EPS Next Y-29.72%

EPS Next 2Y-1%

EPS Next 3Y4.99%

EPS Next 5YN/A

Revenue Next Year51.14%

Revenue Next 2Y41.17%

Revenue Next 3Y52.75%

Revenue Next 5Y181.98%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

LEXX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year LEXX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-1%

EPS Next 3Y4.99%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

LEXX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

LEXARIA BIOSCIENCE CORP

NASDAQ:LEXX (4/25/2025, 8:20:07 PM)

After market: 1.34 -0.01 (-0.74%)

1.35

-0.34 (-20.12%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)04-14 2025-04-14/dmh

Earnings (Next)07-10 2025-07-10

Inst Owners8.04%

Inst Owner Change2.25%

Ins Owners7.81%

Ins Owner Change39.73%

Market Cap23.71M

Analysts82.5

Price Target7.65 (466.67%)

Short Float %4.2%

Short Ratio6.1

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-12.8%

Min EPS beat(2)-30.72%

Max EPS beat(2)5.12%

EPS beat(4)1

Avg EPS beat(4)-18.43%

Min EPS beat(4)-30.72%

Max EPS beat(4)5.12%

EPS beat(8)3

Avg EPS beat(8)-10.08%

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)2

Avg Revenue beat(2)52.42%

Min Revenue beat(2)24.52%

Max Revenue beat(2)80.31%

Revenue beat(4)2

Avg Revenue beat(4)1.7%

Min Revenue beat(4)-52.94%

Max Revenue beat(4)80.31%

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-16.67%

PT rev (3m)-25%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-93.75%

EPS NY rev (1m)-6.36%

EPS NY rev (3m)-33.97%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)-31.5%

Revenue NY rev (1m)0%

Revenue NY rev (3m)8.58%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	45.08
P/FCF	N/A
P/OCF	N/A
P/B	3.32
P/tB	3.57
EV/EBITDA	N/A

EPS(TTM)-0.58

EYN/A

EPS(NY)-0.47

Fwd EYN/A

FCF(TTM)-0.43

FCFYN/A

OCF(TTM)-0.42

OCFYN/A

SpS0.03

BVpS0.41

TBVpS0.38

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-108.13%
ROE	-131.33%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	99.49%
FCFM	N/A

ROA(3y)-124.81%

ROA(5y)-108.73%

ROE(3y)-127.55%

ROE(5y)-113.67%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y9.01%

GM growth 5Y1.71%

F-Score3

Asset Turnover0.06

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	234.78%
Cap/Sales	29.91%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	4.24
Quick Ratio	4.24
Altman-Z	-0.27

F-Score3

WACC8.3%

ROIC/WACCN/A

Cap/Depr(3y)180.28%

Cap/Depr(5y)128.17%

Cap/Sales(3y)61.25%

Cap/Sales(5y)40.91%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)14.71%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-150%

EPS Next Y-29.72%

EPS Next 2Y-1%

EPS Next 3Y4.99%

EPS Next 5YN/A

Revenue 1Y (TTM)36.14%

Revenue growth 3Y-13.6%

Revenue growth 5Y16.11%

Sales Q2Q%20%

Revenue Next Year51.14%

Revenue Next 2Y41.17%

Revenue Next 3Y52.75%

Revenue Next 5Y181.98%

EBIT growth 1Y-72.66%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-48.7%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-50.34%

OCF growth 3YN/A

OCF growth 5YN/A

LEXARIA BIOSCIENCE CORP (LEXX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens